Aurinia Pharmaceuticals (AUPH) EBIAT (2018 - 2025)
Historic EBIAT for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $31.6 million.
- Aurinia Pharmaceuticals' EBIAT rose 11986.76% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.8 million, marking a year-over-year increase of 44514.46%. This contributed to the annual value of $5.8 million for FY2024, which is 10737.25% up from last year.
- As of Q3 2025, Aurinia Pharmaceuticals' EBIAT stood at $31.6 million, which was up 11986.76% from $21.5 million recorded in Q2 2025.
- Aurinia Pharmaceuticals' 5-year EBIAT high stood at $31.6 million for Q3 2025, and its period low was -$50.4 million during Q1 2021.
- In the last 5 years, Aurinia Pharmaceuticals' EBIAT had a median value of -$13.4 million in 2023 and averaged -$15.0 million.
- In the last 5 years, Aurinia Pharmaceuticals' EBIAT plummeted by 9427.35% in 2021 and then skyrocketed by 287963.99% in 2025.
- Aurinia Pharmaceuticals' EBIAT (Quarter) stood at -$33.3 million in 2021, then grew by 21.84% to -$26.0 million in 2022, then dropped by 3.18% to -$26.9 million in 2023, then surged by 105.32% to $1.4 million in 2024, then surged by 2107.91% to $31.6 million in 2025.
- Its EBIAT stands at $31.6 million for Q3 2025, versus $21.5 million for Q2 2025 and $23.3 million for Q1 2025.